Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Patent
1995-04-25
1998-05-19
Criares, Theodore J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
514254, A61K 3156, A61K 31495
Patent
active
057536414
ABSTRACT:
Disclosed is an improved treatment for men with benign prostatic hyperplasia (BPH), involving combination therapy of a 5.alpha.-reductase inhibitor, e.g. a 17.beta.-substituted 4-azasteroid, a 17.beta.-substituted non-azasteroid, 17.beta.-acyl-3-carboxy-androst-3,5-diene, benzoylaminophenoxybutanoic acid derivative, fused benz(thio)amide or cinnamoylamide derivative, aromatic 1,2-diethers or thioethers, aromatic ortho acylaminophenoxy alkanoic acids, ortho thioalkylacylaminophenoxy alkanoic acids, pharmaceutically acceptable salts and esters thereof, and particularly finasteride, in combination with an .alpha..sub.1 -adrenergic receptor blocker, i.e., terazosin. The combination provides therapy at the molecular level for the underlying cause of the disease as well as providing symptomatic relief. Pharmaceutical compositions useful for treatment are also disclosed.
REFERENCES:
patent: 3511836 (1970-05-01), Hess
patent: 3527761 (1970-09-01), Archibald et al.
patent: 3920636 (1975-11-01), Takahashi et al.
patent: 3980650 (1976-09-01), Nauta
patent: 4026894 (1977-05-01), Winn et al.
patent: 4188390 (1980-02-01), Campbell
patent: 4220775 (1980-09-01), Rasmusson et al.
patent: 4315007 (1982-02-01), Manoury
patent: 4377584 (1983-03-01), Rasmusson et al.
patent: 4732897 (1988-03-01), Cainelli et al.
patent: 4760071 (1988-07-01), Rasmusson et al.
patent: 4845104 (1989-07-01), Carlin et al.
patent: 4859681 (1989-08-01), Rasmusson et al.
patent: 4882319 (1989-11-01), Holt et al.
patent: 4888366 (1989-12-01), Holt et al.
patent: 4910226 (1990-03-01), Holt et al.
patent: 5212176 (1993-05-01), Kyncl et al.
Patrick Walsh, "Treatment of Benign Prostatic Hyperplasia", New England Journal of Medicine, 335 (8):586-587, Aug. 22, 1996.
Herbert Lepor et al., "The Efficacy of Terazosin, Finasteride, or Both in Benigh Prostatic Hyperplasia", New England Journal of Medicine, 335(8):533-539, Aug. 22, 1996.
Jonathan M. Vapnek et al., "Combination Medical Therapy for Symptomatic Benign Prostatic Hyperplasia", Abstracts Western Section AUA 72nd Annual Meeting, Jul. 28-Aug. 1, 1996.
Kumamoto et al., Clinical Efficacy of Oxendolene (Antiandrogen) and Bunazosin Hydrochloride (Alplha-Adrenergic Blocker) in the Treatment of Prostatism, 33 Hinyokika Kiyo 1921-1942 (1987).
Hedlund et al., Effects of Prazosin in Patients with BPH, 130 J. Urol., pp. 275-278 (1983).
Nagatomo et al., Adrenergic and Serotonergic Receptor-Blocking Potencies of Terazosin, a New Antihypertensive Agent, as Assessed by Radioligand Binding Assay, 35(4) Chem. Pharm. Bull. 1629-1632 (1987).
The Finasteride Study Group, Finasteride (MK-906) in the Treatment of Benign Prostatic Hyperplasia, 22 Prostate 291-299 (1993).
Caine et al., The Effect of Nicergoline on the Lower Urinary Tract Muscle, Chem. Abstr., CA102(11):90035s (1993).
Caine et al., The Use of Alpha-Adrenergic Blockers in Benign Prostatic Obstruction, 48 Br. J. Urol. 255-263 (1976).
Neri et al., Effects of a Novel Nonsteroidal Antiandrogen on Canine Prostatic Hyperplasia 10 Invest. Urol. 123-130 (1972).
Nieschlag & Loriaux, Radioimmunoassay for Plasma Testosterone, 10 Z. klin. Chem. u. klin. Biochem. 164-168 (1972).
Mandal & Vaidyanathan, Non-Operative Management of Symptomatic Benign Prostatic Hyperplasia, 6(2) Indian J. of Urol. 45-50 (1990).
The Daily (Tuesday, May 7, 1996), "New Data on Proscar, Abbott's Hytrin Show Conflicting Results".
Wall Street Journal (Tuesday, May 7, 1996), "Study Finds Abbott's Prostate Drug is Much More Effective than Merck's", p. B4.
US News & World Report, May 20, 1996, "Zapping a problem prostate".
Gormley Glenn J.
Stoner Elizabeth
Criares Theodore J.
Fitch Catherine D.
Merck & Co. , Inc.
Nicholson William H.
LandOfFree
Method of treatment for benign prostatic hyperplasia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treatment for benign prostatic hyperplasia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treatment for benign prostatic hyperplasia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1853138